Home > Keywords > Thématique > Science

Science

Articles

  • Séminaire M&M’s – Muscle Monday Seminars of the Institute’s Myology Centre for Research on January 17, 2022
    17 January 2022, by Elodie DORMES

    Michel Khrestchatisky (CNRS Research Director, Director of the Institute for Neurophysiopathology) Co-Founder & Scientific Counsel of Vect-Horus presents "Development of molecular vectors for targeted delivery of RNAi via receptor-mediated transport" at the Muscle Monday Seminars organized by the Institute’s Myology Centre for Research.

  • Society for the study of Blood-Brain interfaces SEISC 2019 congres
    27 November 2019, by Elodie DORMES

    Stéphane GIRARD will present iPS cell-derived model of the human blood-brain-barrier on Friday 15, Nov Session 1 of the Society for the study of Blood-Brain interfaces SEISC 2019 congres in Paris

  • Vect-Horus participates to the event Radiopharmaceuticals & Imaging on March 14, 2023
    9 March 2023, by Elodie DORMES

    Cedric MALICET, Oncology Department Manager, will participate to the Radiopharmaceuticals & Imaging event next week ! You can book a meeting with him directly via the partnering system to discuss company developments on its theranostic agents.

  • Oligonucleotides for CNS Congress from February 22-24, 2021
    2 February 2021, by Elodie DORMES

    Dr Michel KHRESTCHATISKY will join the session dealing with “Exploring Extra-Hepatic Delivery to Relevant Targets within the CNS & Muscle” and give a talk to describe the use of VECT-HORUS “Molecular Vectors for Targeted Delivery of Oligonucleotides”.

  • AD/PD 2019​ International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders in LISBON
    28 January 2019, by Jonathan NOWAK

    Marion DAVID and Romy COHEN will present the “Development of vectors that cross the blood brain barrier to enhance CNS drug delivery in neurodegenerative diseases” in session A: β-Amyloid Diseases poster n°ADPD9-1832

  • Two new patents protecting VECTrans® technology issued in several major countries
    28 January 2019, by Jonathan NOWAK

    Press release Communiqué de presse
    VECT-HORUS, a biotechnology company that designs and develops peptide vectors for addressing drugs or imaging agents to the brain and other organs, announces the strengthening of its patent portfolio with the granting of two patents in several major countries and particularly in the United States.
    These two patents protect peptide vectors that facilitate the targeting of drugs or imaging agents to organs, including the brain. Entitled “Peptide (…)

  • 3rd Annual RNAi-Based Therapeutics Summit from April 19th to 21th, 2022, in Boston
    12 April 2022, by Elodie DORMES

    Michel KHRESTCHATISKY, Scientific Counsel, will have a talk entitled “Development of Molecular Vectors for Targeted Delivery of RNAi” and Elodie DORMES, Sr BD Manager, will also be there and pleased to meet you in person during the summit.

  • Vect-Horus focuses on Target engagement and intracellular delivery of LDLR conjugates to design new targeted drug therapies
    27 November 2019, by Elodie DORMES

    Varini et al. J Control Release 2019
    Targeted delivery to specific tissues and subcellular compartments is of paramount importance to optimize therapeutic or diagnostic interventions while minimizing side-effects. Using recently identified LDL receptor (LDLR) -targeting small synthetic peptide-vectors conjugated to model cargos of different nature and size, we investigated in LDLR-expressing cells the impact of vector-cargo molecular engineering and coupling valency, as well as the (…)

  • NTSR2 is induced in astrocytes and brain endothelial cells in relation to neuroinflammation following pilocarpine-induced seizures in rats
    30 September 2021, by Elodie DORMES

    Neurotensin (NT) acts as a primary neurotransmitter and neuromodulator in the CNS and has been involved in a number of CNS pathologies including epilepsy. NT mediates its central and peripheral effects by interacting with the NTSR1, NTSR2, and Sort1/NTSR3 receptor subtypes. To date, little is known about the precise expression of the NT receptors in brain neural cells and their regulation in pathology. In the present work, we studied the cellular distribution of the NTSR2 protein in the rat (…)

  • Vect-Horus successfully completes the VECtoBrain project
    28 January 2019, by Jonathan NOWAK

    Ths project was supported from 2009 to 2013 by the Agence Nationale de la Recherche (ANR) BiotecS Call 2009.
    The project was coordinated by VECT-HORUS (Dr. Guillaume Jacquot) and involved the UMR7259 laboratory (CNRS and Aix-Marseille University, Director Dr Michel Khrestchatisky), the U705 laboratory (Director, Pr. Jean-Michel Scherrmann) of INSERM and the SIMOPRO laboratory (Director Dr. Vincent Dive) of the CEA.
    This project also received support (label) from the EUROBIOMED Biocluster.